Financing co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch Proceeds will be used to develop next-generation T-cell receptor-based therapies for cancer treatment TCR therapy pioneer and industry veteran Dr Bent Jakobsen appointed as Chairman of the Board Basel, Switzerland, May 3, 2022. Engimmune Therapeutics AG (“Engimmune”), a Swiss biotech company developing novel […]